Medicare受益者中骶神经调节与A型肉毒毒素注射治疗膀胱过度活动症的临床医生与地理差异
本研究基于2014-2016年100%付费服务Medicare受益者横断面数据,分析首次接受骶神经调节(SNM)或onabotulinumtoxinA注射治疗膀胱过度活动症(OAB)的利用差异。共48,580例受益者接受SNM(47.1%)或onabotulinumtoxinA注射(52.9%)。临床医生和医院转诊区域(HRR)的变异大于患者个体特征,SNM对比注射的调整中位比值比(MOR)在临床医生层面为33.1,HRR层面为4.24。
要点
- 临床医生和地理区域对OAB微创治疗选择的影响大于患者个体特征。
- SNM与onabotulinumtoxinA注射的选择在临床医生间的变异极大(MOR 33.1)。
- SNM测试术式(stage 1 vs PNE)的选择也存在显著临床医生间变异(MOR 13.12)。
核心结论
- 在首次接受SNM或onabotulinumtoxinA注射的Medicare受益者中,操作医生和地理区域存在显著利用差异,非临床因素(患者就诊医生和居住地)是美国OAB微创治疗利用的重要驱动因素。
研究设计与样本
- 横断面研究,纳入2014-2016年100%付费服务Medicare受益者中首次接受SNM测试术或onabotulinumtoxinA注射的病例,共48,580例。
主要发现
- 总体48,580例受益者接受SNM(47.1%)或onabotulinumtoxinA注射(52.9%)。
- SNM对比onabotulinumtoxinA注射的调整MOR:临床医生33.1,HRR 4.24。
- stage 1永久电极置入对比PNE的调整MOR:临床医生13.12,HRR 2.44。
- 临床医生和HRR的变异比患者个体特征更具影响力。
临床怎么用
- 临床决策时应意识到医生和地理因素对OAB微创治疗选择的显著影响,促进治疗选择的标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate clinician- and geographic-level variation in utilization of sacral neuromodulation (SNM) and onabotulinumtoxinA injections as index treatment for overactive bladder (OAB) among United States Medicare beneficiaries. METHODS: This is a cross-sectional study of a 100% sample of fee-for-service Medicare beneficiaries undergoing first-time SNM test procedures or onabotulinumtoxinA injections from 2014-2016. The primary outcomes were clinician- and geographic-level variation in utilization of SNM or onabotulinumtoxinA injections. Secondary outcomes included variation in use of SNM test procedures (percutaneous nerve evaluation [PNE] and stage 1 permanent tined lead placement [stage 1]). Geographic region was defined using hospital referral regions (HRRs). Mixed-effect logistic regression models were used to calculate the median odds ratio (MOR) for clinician and HRR (higher MOR = greater variability between groups) and to identify individual-level predictors of utilization. RESULTS: Overall, 48,580 Medicare beneficiaries underwent SNM (47.1%) or onabotulinumtoxinA injections (52.9%) during the study period. There was a considerable amount of variation according to clinician and HRR, which were more influential than patient-level characteristics in the type of procedure received. The adjusted MOR for SNM versus onabotulinumtoxinA injections was 33.1 for clinician and 4.24 for HRR. For stage 1 versus PNE, the MOR was 13.12 for clinician and 2.44 for HRR. CONCLUSION: Among Medicare beneficiaries undergoing first-time SNM or onabotulinumtoxinA injections, there was considerable variation according to performing clinician and geographic region. These findings suggest that non-clinical variables-who a patient sees and where they live-are significant drivers of minimally invasive OAB therapy utilization in the United States.
引用
- Dreyfuss LD, Wang L, Nik-Ahd F, et al. Clinician- and Geographic-level Variation in Utilization of Sacral Neuromodulation and OnabotulinumtoxinA Injections Among Medicare Beneficiaries With Overactive Bladder. Urology. 2025. PMID: 41197836. doi:10.1016/j.urology.2025.10.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。